2. Academic Validation
  3. SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition

SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition

  • Bioorg Med Chem Lett. 2003 Feb 10;13(3):405-8. doi: 10.1016/s0960-894x(02)00996-4.
Rolf van Hes 1,  Pieter Smid,  Cees N J Stroomer,  Koos Tipker,  Martin Th M Tulp,  Jan A M van der Heyden,  Andrew C McCreary,  Mayke B Hesselink,  Chris G Kruse
Affiliations

Affiliation

  • 1 Solvay Pharmaceuticals Research Laboratories, PO Box 900, 1380 BA Weesp, The Netherlands.
PMID: 12565939 DOI: 10.1016/s0960-894x(02)00996-4
Abstract

In this paper, SLV310 is presented as a novel, potential antipsychotic displaying the interesting combination of potent dopamine D(2) receptor antagonism and serotonin reuptake receptor inhibition in one molecule. As such, SLV310 could be useful in treating a broad range of symptoms in schizophrenia. This paper describes the structure-activity relationship in a series of compounds leading to SLV310 (6b, 2-[4-[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-yl]-butyl]-phthalimide) together with pharmacological data showing the unique profile of this compound.

Figures
Products